Wells Fargo
BCAX

Wells Fargo’s Bicara Therapeutics BCAX Stock Holding History

Wells Fargo’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$298K Sell
14,977
-20,266
-58% -$349K ﹤0.01% 4456
2025
Q4 		$593K Buy
35,243
+9,319
+36% +$159K ﹤0.01% 4362
2025
Q3 		$409K Buy
25,924
+4,223
+19% +$47.3K ﹤0.01% 4450
2025
Q2 		$202K Buy
21,701
+11,448
+112% +$136K ﹤0.01% 4767
2025
Q1 		$134K Buy
10,253
+226
+2% +$3K ﹤0.01% 4937
2024
Q4 		$175K Buy
+10,027
New +$209K ﹤0.01% 4873

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Wells Fargo's BCAX Position: Q1 2026 in Review

Wells Fargo reduced its Bicara Therapeutics (BCAX) stake by 58% in Q1 2026, selling an estimated $349K and leaving 14,977 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #4456.

Wells Fargo first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. The position peaked at $593K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Wells Fargo held 14,977 shares of Bicara Therapeutics worth $298K as of Q1 2026.
  • Wells Fargo sold 20,266 Bicara Therapeutics shares in Q1 2026, an estimated $349K.
  • Bicara Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4456 holding.
  • Wells Fargo first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Wells Fargo's Bicara Therapeutics position peaked at $593K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.